FOLFIRI plus bevacizumab (B) as neoadjuvant treatment for potentially resectable colorectal cancer patients (pts) with liver metastasis: A phase II trial.

@inproceedings{Nasti2012FOLFIRIPB,
  title={FOLFIRI plus bevacizumab (B) as neoadjuvant treatment for potentially resectable colorectal cancer patients (pts) with liver metastasis: A phase II trial.},
  author={Guglielmo Nasti and Alessandro Ottaiano and Carmen Romano and Francesco Izzo and Paolo Delrio and Vittorio Albino and Pasqualina Giordano and Maria Carmela Piccirillo and Gennaro Daniele and S Lastoria and Corradina Carac{\'o} and Cecilia Arrichiello and Elisabetta De Lutio and Piera Maiolino and Fabiana Tatangelo and Rosario Vincenzo Iaffaioli},
  year={2012}
}
e14130 Background: Irinotecan-based chemotherapy plus B was shown to be effective and safe in both first- and second-line treatment for metastatic colorectal cancer (mCRC) pts.We designed this trial to assess whether the combination of FOLFIRI + B given to untreated, potentially resectable mCRC pts was feasible and active. Methods: Phase II, single arm trial with 1-year progression-free rate (PFR) as primary end-point. A sample size of 39 pts was calculated to detect a 70% ± 12% 1-year PFR. The… CONTINUE READING

Topics from this paper.